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ABSTRACT 
Rubella causes disease in the fetus. Immunity to rubella is therefore routinely screened in pregnant 
women. In this retrospective observational study, we assessed both the effectiveness of screening 
for rubella and the levels of immunity to rubella in the population of a north London antenatal clinic. 
Risk factors for non-immunity to rubella and changes in levels of immunity over time were studied. 
Almost all women were screened for rubella immunity (99.8%). The majority were immune (92.8%). 
Women booking in earlier years within the study period showed higher levels of immunity. Every 
increasing year gave women an odds ratio of 0.86 (CI:0.80,0.92) of being immune. Age was 
associated with immunity to rubella, with a 5.4% (CI:4.0%,6.8%) increased likelihood of immunity for 
every year older. Country of birth was associated with differences in susceptibility, with those from 
countries that do not offer MMR vaccine having an odds ratio of 0.710 (CI:0.514,0.906) of being 
immune to rubella. This study suggests there has been significant decline in immunity to rubella over 
the past 5 years. Age and country of birth are significant risk factors for non-immunity to rubella. 
Those at risk should be screened for rubella immunity and offered vaccine prior to conception, 
including post-partum. 
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INTRODUCTION 
Rubella is an important pathogen for the fetus. Primary infection in the first 
trimester can cause congenital heart disease, sensorineural hearing loss 
and cataracts (Public Health England, 2013). Prior to the UK vaccination 
programme, around 1 in 5 women remained susceptible to rubella with 
hundreds of cases of congenital rubella syndrome (CRS) (Tookey, 2004). 
Rubella infection and CRS are now rare in the UK, with twenty infants 
diagnosed with CRS since 2000 (Tookey, 2014). In the majority of these 
cases rubella was acquired abroad (Tookey, 2014). Worldwide, however, 
an estimated 110,000 babies are born with CRS every year (Cutts & 
Vynnycky, 1999).  
 
In the UK, a national immunisation programme for adolescent girls began in 
1970 using measles/rubella vaccine (Public Health England, 2013). This 
was later replaced by universal measles/mumps/rubella (MMR) vaccine for 
toddlers in 1988 (Public Health England, 2013).  Since the 1970s, women at 
antenatal booking clinics have been routinely screened for rubella immunity 
through testing for IgG antibodies specific for rubella. Any found to be non-
immune are recommended to receive MMR vaccine postpartum. This 
activity will shortly cease, because the Joint Committee on Vaccination and 
Immunisation has recently recommended that immunity to rubella should 
be assessed solely by MMR vaccination history (Public Health England, 
2016).  
 
Because of this planned change, we took the opportunity to review our 
screening programme for antenatal testing of rubella immunity before 
screening ceases. Levels of immunity to rubella in the antenatal population 
of a north London hospital were determined. Risk factors for non-immunity 
to rubella and changes in levels of immunity over the study period were 
assessed. 
 
MATERIALS AND METHODS 
We undertook a retrospective analysis of attendances to antenatal booking 
appointments at the Royal Free Hospital. Attendances between January 
2010 and September 2014 were included in the study. At each booking 
appointment midwives collected information on a standard electronic pro 
forma. This information was self-reported and included age, country of 
birth, ethnic origin, previous pregnancies and estimated gestational age of 
the fetus.  
 
At booking, every woman was offered screening for immunity to rubella. 
Rubella IgG was measured using the Abbott ARCHITECT.1 Positivity for 
rubella IgG was defined as detection of IgG antibodies at a level of greater 
than or equal to 10 IU/mL, as recommended by the UK National Screening 
Committee (UK National Screening Committee, 2003). Results were 
matched with antenatal booking information using hospital number and 
date of test. 
 
Demographic data from electronic booking appointment records were 
analysed to identify risk factors for rubella non-immunity. Individuals were 
defined as being from a high-risk country for rubella non-immunity if their 
country of origin was listed as a WHO target country for rubella vaccination 
(World Health Organsiation, 2012) or if the country of origin does not have 
rubella vaccination as part of the routine childhood immunization schedule 
(World Health Organisation, 2016). 
 
Previous pregnancy was defined as previous live births, stillbirths, 
miscarriage or terminations of pregnancy as reported by the women at their 
first booking appointment in the study period. 
 
Ethnicity was self-reported and categories included ‘African’, ‘Any other 
Asian background’, ‘Any other Black background’, ‘Any other ethnic group’, 
‘Any other mixed background’, ‘Any other White background’, 
‘Bangledeshi’, ‘British’, ‘Caribbean’, ‘Chinese’, ‘Indian’, ‘Irish’, ‘Not Known’, 
‘Not Stated’, ‘Pakistani’, ‘Unknown’, ‘White and Asian’, ‘White and Black 
African’ and ‘White and Black Caribbean.’ For simplicity of analysis, these 
were grouped into White (Any other White background, British and Irish), 
‘Non-white or mixed’ (‘African’, ‘Any other Asian background’, ‘Any other 
Black background’, ‘Any other ethnic group’, ‘Any other mixed background’, 
‘Bangledeshi’, ‘Caribbean’, ‘Chinese’, ‘Indian’, ‘Pakistani’, ‘White and 
Asian’, ‘White and Black African’ and ‘White and Black Caribbean’) and 
Unknown (‘Not Known’, ‘Not Stated’, ‘Unknown’). 
 
Age of women was stratified into six cohorts <20, 20-24, 25-29, 30-34, 35-
39, >39 years old. Year of booking was taken as the date of the electronic 
maternal booking form. 
 
Analysis was carried out in IBM SPSS Statistics v20. The frequency of 
rubella non-immunity was calculated by year of first booking, age, ethnicity, 
previous pregnancy, country of birth and number of bookings within the 
study period. Differences in proportions between groups were compared 
using Pearson’s chi-squared test. Logistic regression modeling was used to 
investigate the relationships between the effects on rubella immunity of 
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year of first booking, age, ethnicity, previous pregnancy, country of birth 
and number of bookings within the study period  
 
RESULTS 
16,250 booking appointments from 14,118 individuals were identified 
during the study period. Demographic details of these individuals are 
shown in Table 1. Approximately half (7,840/14,118, 55.5%) of individuals’ 
reported their ethnic background as white. The mean age at their first 
booking appointment in the study period was 31 years (range 14-54). Just 
over half of individuals reported a previous pregnancy at their first booking 
appointment in the study period (8,101/14,118, 57.3%). 
 
14,100/14,118 (99.8%) of individuals had rubella IgG tested on first booking 
within the study period. 13,088/14,100 (92.8%) were immune to rubella on 
their initial booking. 
  
Univariate analysis to investigate factors for non-immunity to rubella.  
Age 
Age was a significant predictor of immunity to rubella. Those aged under 20 
showed the lowest levels of rubella immunity (80.8%) compared with those 
aged 20 to 24 (89.4%), 25 to 29 (92.9%), 30 to 34 (94.5%), 35-39 (94.2%) 
and over 39 (92.8%) (p<0.001). See Figure 1 and Table 2. 
 
Ethnicity. 
92.1% (13,003/14,118) of women declared an ethnicity at booking. Those 
identifying as a ‘white’ ethnicity were more likely to be immune to rubella 
(7,340/7,830, 93.7%) compared to those of other ethnicities (4,743/5,173, 
91.7%) p<0.001). 
 
Year of booking 
Differences in rubella immunity in different years of booking within the study 
period was analysed using univariate analysis. Women booking in 2010 
showed significantly higher rates of immunity (94.9%), which declined 
consistently in subsequent years: 2011, 94.0%; 2012, 92.1%; 2013, 90.7%; 
2014, 91.2%. (p<0.001). See Table 3. 
 
Number of bookings in study period 
Number of booking appointments in the study period was associated with 
rubella immunity in univariate analysis. Immunity in those with only one 
booking was significantly lower (n 11,255/12,154; 92.6%) than in those with 
multiple bookings (n=1,835/1,946 94.2%) (p=0.01). 
 
Previous pregnancy 
At individuals’ first booking within the study period 6017/14,118 (42.6%) 
reported no previous pregnancies. Previous pregnancy was not identified 
as significant risk factor for rubella non-immunity at booking in univariate 
analysis. (468/6,010 7.8% vs 544/8,010 6.7%, p=0.111)  
 
Country of birth 
Country of birth was investigated as a risk factor for non-immunity to rubella 
IgG. 10,565/14,118 (74.8%) of individuals had both a country of birth 
recorded and a rubella IgG test performed. The rate of non-immunity in 
those with a country of birth recorded was not significantly different from 
those who did not have a country of birth recorded (7.4% vs 8.2%, p=0.12). 
Being from a country at risk of rubella non-immunity significantly increased 
the risk of being rubella non-immune at booking (221/2,226, 9.9% vs 




Logistical regression was used to investigate the effect size of these 
individual factors and to minimise confounding. Age, ethnicity, previous 
pregnancy, year of booking, number of bookings within the study period 
and whether born in a high risk country for rubella non-immunity were 
analysed using a multivariate binary regression model (Table 4). 
Age remained a significant predictor of immunity to rubella. For every year 
older there was a 5.4% increased chance of being immune to rubella (CI: 
4.0%, 6.8%, p<0.001). 
Being born in a high risk country for rubella non-immunisation was a 
significant predictor of non-immunity. Those born in a high risk country 
were around 30% more likely to lack rubella immunity (OR 0.710 CI: 0.514, 
0.906, p=0.001). 
Year of initial booking within the study period was associated with 
differences in immunity to rubella. Each successive year of the study period 
was associated with a 14.4% increased chance of non-immunity (OR: 
0.856, CI: 0.797, 0.915, p<0.001). 
Ethnicity and number of bookings within the study period failed to reach 
significance in the multivariate analysis as predictors of rubella non-
immunity in antenatal women. Previous pregnancy remained a non-
significant predictor of non-immunity to rubella in the multivariate analysis. 
 
DISCUSSION 
The rubella screening programme exists to assess the susceptibility of 
pregnant women to rubella infection. In this study over 99% of the antenatal 
population was screened for rubella immunity, confirming good 
implementation of screening in our hospital. 
This study confirms that the vast majority of women seeking antenatal care 
in North London are immune to rubella. Screening showed an overall 
immunity to rubella of 92.8% amongst women at first booking. 
The range of herd immunity seen in this study is above minimum estimates 
of critical prevalence of rubella immunity required to prevent an outbreak 
(Plans, 2013).  However, it is below the 95% immunity level recommended 
for childbearing women by the 2003 WHO European strategic plan (World 
Health Organisation, 2003). As such, clinicians should be vigilant for 
women at risk of rubella susceptibility and offer screening or vaccination as 
appropriate. 
Immunity across the study period decreased consistently in later years. 
Between 2010 and 2014 immunity in our cohort significantly waned from 
94.9% to 91.2%.   The decrease in immunity over time in our antenatal 
population supports the findings of other studies. Between 2004 and 2009, 
the susceptibility of childbearing women was found to increase by 60% in 
England (Byrne et al, 2012). Over a similar time period in the West 
Midlands, susceptibility in pregnant women increased around five times to 
around 7% (Skidmore et al, 2014). These figures are broadly similar to our 
findings. Lower levels of rubella immunity in later years may reflect the fact 
that rubella is no longer circulating in the UK. Alternatively it may reflect 
decreasing vaccine uptake. This emphasizes the importance of maintaining 
herd immunity through screening at-risk women and offering universal 
MMR vaccine.  
Country of birth was associated with differences in immunity to rubella. 
Women born in countries where vaccination programmes are known to be 
inadequate or where vaccination is not universally recommended were at 
increased risk of rubella non-immunity. North London has a highly mobile 
population and high levels of immigration. Recent waves of immigration 
may explain declining immunity in our population. This hypothesis is 
supported by our findings that country of birth is a significant predictor of 
non-immunity. Other studies have previously identified women of 
childbearing age from non-white ethnic groups as significantly more likely 
to lack immunity to rubella (Byrne et al, 2012; Tookey et al, 2002).  
 
Risk factors for non-immunity to rubella also include age, with younger 
women being significantly more at risk than older women. Indeed women 
under 20 at first booking had the lowest levels of immunity, with rubella IgG 
positivity at just 80.8%. The levels of susceptibility to rubella in this age 
group are around 2.5 times higher than in those aged 40 and over.  
The reasons for decreases in immunity with younger women and in later 
years is unclear. Decreases in immunity may relate to declining rates of 
vaccine uptake, explaining why levels of immunity are lower in younger 
women and in later years. Unfortunately, our dataset did not include 
information on vaccination history. Previous, widely reported data showed 
that vaccine uptake for the MMR vaccine fell after 1998 associated with the 
MMR-autism scandal (Jansen et al, 2003). The youngest women in our 
cohort, aged between 14 and 25 and with the lowest levels of rubella 
immunity would have been vaccinated between 1990 and 2002. Thus if low 
immunity in our sample was due to poor uptake, this may be in part 
attributable to the Wakefield scandal. 
 
Furthermore, wild-type rubella virus no longer circulates in the UK. 
Immunity in more recent years is therefore solely attributable to 
vaccination. Vaccination may not produce antibody titres as high as natural 
infection. Furthermore, lack of exposure to circulating wild-type rubella will 
prevent antibody boosting via secondary immune responses. Previous data 
supports this, showing IgG levels in vaccinated individuals decrease in 
relation to the time elapsed since vaccination.  In Canada, a retrospective 
study showed 1/3 of vaccinated individuals had IgG levels that were below 
the designated threshold of immunity after 15 years. (Lai et al, 2015) Given 
sustained elimination of rubella virus in Canada, it is argued low levels of 
rubella-specific antibodies below the designated threshold for immunity 
may be sufficient to prevent spread of infection. In vitro data supports this, 
with college age students with antibody levels below  
 
 As our data did not include information on individuals’ vaccination history 
these effects could not be assessed, especially in the knowledge that many 
foreign-born women may have received different vaccination schedules. 
Our study used country of birth as a proxy measure for likelihood of 
vaccination in childhood. In the absence of individuals’ vaccination records, 
a more accurate measure may be length of residence in the UK. This study 
could also not investigate the effect of other factors such as socioeconomic 
class due to lack of data. 
 
This study is a topical assessment of immunity to rubella in an at-risk 
population just before routine screening ceases. It confirms that the vast 
majority of antenatal women attending our clinic show immunity to rubella. 
As such, screening is unlikely to have benefit for these women. There 
exists a small but significant proportion of women potentially susceptible to 
rubella infection. By stopping routine screening these women are unlikely to 
be identified as potentially susceptible. We have identified risk-factors 
which may aid identification of those potentially susceptible to rubella 
infection.  
 
One potential strategy for increasing herd immunity would be to selectively 
screen patients in high-risk categories and offer post-partum vaccination if 
they were found to be potentially susceptible. The strategy of identifying 
those at risk of non-immunity using risk factors is unclear given the 
assertion that previously vaccinated individuals with antibodies below the 
threshold may in fact have sufficient immunity to prevent infection  
 
Stopping routine screening of rubella immunity in antenatal women will also 
mean a loss of valuable data with which to analyse changes in immunity 
over time and demographics. This is especially pertinent given the changes 
in immunity demonstrated in this study.  
 
This study is limited by technical problems with assessing rubella immunity 
and the definition of susceptibility. The accepted and recommended practice 
of using a 10 IU/mL threshold for immunity has been reported to lack 
sensitivity.(ref) This may lead to some individuals with a concentration of 
rubella IgG below the designated immunity threshold being incorrectly 
labelled as ‘susceptible’ to rubella infection. Unfortunately, for individual’s 
falling below the 10 IU/mL threshold for immunity a second, gold-standard 
reference assay was not uniformly employed to assess immunity.  As such 
we cannot ascertain which proportion of our population were falsely deemed 
‘potentially susceptible’ to rubella infection due to poor sensitivity of the 
assay.  
 
In a recent series, over half of those samples falling below immunity 
threshold when tested using the Abbott Architect assay tested positive for 
antibodies by immunoblot and neutralization assays. (Bouthry et al, 2016). 
Around 2/3 of these false-negatives fell into the equivocal category (5-10 
IU/mL). This supports previous modelling which has suggested antibody 
levels <5 IU/mL may more accurately represent women susceptible to 
infection (ai et al, 2015). This may mean our analysis overestimates 
susceptibility substantially despite calibration against an international 
standard. Provide equivicol 5-10 
 
It does not, however, describe rubella immunity in the general population, 
which is also important for providing the protection of herd immunity to the 
7.7% of our antenatal population susceptible to rubella infection.  
 
Younger women are also significantly more likely to be susceptible to 
rubella infection. Further efforts must be made to offer vaccination to young 
women, who have been consistently shown to have higher levels of 
susceptibility to rubella. 
At present, seronegative women are protected while they remain in the UK, 
because there is no evidence of rubella circulation. However, they could be 
exposed through travel abroad or by contact with imported cases of rubella. 
An important practice point is that healthcare professionals, especially GPs 
and obstetricians, should actively offer screening for rubella immunity to 
women born outside the UK and administer vaccine to those who are found 
to be seronegative. Decreases in immunity over time and in younger 
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 Figure 1: Age-stratified susceptibility to rubella at first booking appointment 




















































Women tested  
for rubella 
immunity (%) 
Women  immune 
to rubella (n) 
∑=13,088 
Susceptibility of 
women to rubella(%) 
ETHNIC BACKGROUND      
White 7840 7830 99.9 7340 6.3 
Non-white or mixed 5181 5173 99.8 4743 8.3 
Unknown 1097 1097 100% 1005 8.4 
      
YEAR OF BOOKING      
2010 3530 3521 99.7 3340 5.1 
2011 3208 3204 99.9 3011 6.0 
2012 2998 2993 99.8 2756 7.9 
2013 2750 2750 100 2493 9.3 
2014 1632 1632 100 1488 8.8 
      
PARITY      
0 6017 6010 99.9 5542 7.8 
1+ 8101 8090 99.9 7546 6.7 
      
AGE      
<20 294 293 99.7 237 19.1 
20-24 1756 1753 99.8 1539 12.2 
25-29 3816 3813 99.9 3543 7.1 
30-34 4860 4855 99.8 4589 5.5 
35-39 2677 2673 99.9 2517 5.8 
>39 715 713 99.7 662 7.2 
















<20 294 293 237 56 80.9% 
20-24 1756 1753 1539 214 87.8% 
25-29 3816 3813 3543 270 92.9% 
30-34 4860 4855 4589 266 94.5% 
35-39 2677 2673 2517 156 94.2% 
>39 715 713 662 51 92.8% 
Table 2: Rubella IgG positivity in antenatal women at first booking 
























2010 3530 3521 3340 181 94.9% 
2011 3208 3204 3011 193 94.0% 
2012 2998 2993 2756 237 92.1% 
2013 2750 2750 2493 257 90.7% 
2014 1632 1632 1488 144 91.2% 
Table 3: Rubella IgG positivity in antenatal women stratified by year of first 
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